NATCO PHARMA
Limited
RESULTS FOR THE
SECOND QUARTER ENDED SEP'2017
The results of
NATCO PHARM Limited for the second quarter ended Sep'2017 are placed here under.
Decl : This does not constitute a Buy/Sell/Hold Recommendation.
| NATCO
PHARMA |
Sep '17 |
Jun '17 |
Mar '17 |
Dec '16 |
Sep '16 |
| Net Sales |
426.7 |
428.1 |
577.8 |
642.86 |
415.21 |
| Other
Operating Income |
-- |
-- |
-- |
36.15 |
52.65 |
| Total
Income |
426.7 |
428.1 |
577.8 |
679.01 |
467.86 |
| EXPENDITURE |
|
|
|
|
|
| Consumption
of Raw Materials |
81.1 |
128.6 |
101 |
147.66 |
141.27 |
| Purchase
of Traded Goods |
7.9 |
25.6 |
5.6 |
27.28 |
42.67 |
| Increase/Decrease
in Stocks |
23.9 |
-44.8 |
10.6 |
30.48 |
-0.18 |
| Employees
Cost |
73.6 |
63.1 |
79.6 |
56 |
55.35 |
| Depreciation |
16 |
15 |
13.5 |
13.69 |
14.1 |
| Other
Expenses |
118.3 |
118.9 |
139.9 |
157.4 |
123.94 |
| P/L Before
Other Inc., Int., Excpt. Items & Tax |
105.9 |
121.7 |
227.6 |
246.5 |
90.71 |
| Other
Income |
5.5 |
3.4 |
-0.6 |
6.12 |
3.18 |
| P/L Before
Int., Excpt. Items & Tax |
111.4 |
125.1 |
227 |
252.62 |
93.89 |
| Interest |
4.2 |
3.9 |
6.4 |
4.64 |
4.2 |
| P/L Before
Tax |
107.2 |
121.2 |
220.6 |
247.98 |
89.69 |
| Tax |
22.8 |
27.5 |
44.2 |
53.14 |
23.47 |
| Net
Profit/(Loss) For the Period |
84.4 |
93.7 |
176.4 |
194.84 |
66.22 |
| Minority
Interest |
-- |
-- |
0.3 |
0.24 |
0.33 |
| Net P/L
After M.I & Associates |
84.4 |
93.7 |
176.7 |
195.08 |
66.55 |
| Equity
Share Capital |
34.9 |
34.9 |
34.9 |
34.86 |
34.83 |
| Basic EPS |
4.82 |
5.59 |
10.1 |
11.18 |
3.79 |
| Diluted
EPS |
4.82 |
5.58 |
10.09 |
11.16 |
3.78 |
|
|
|
|
|
|
| MARKET
PRICE |
956.75 |
|
|
|
|
| PE RATIO |
49.62 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No comments:
Post a Comment